In situ gene therapy for prostate cancer: Immunomodulatory approaches

Expert Opinion on Biological Therapy

Volumn 1, Issue 3, 2001, Pages 481-495

  Thompson, T C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Gene therapy; Il 12, metastasis; Prostate cancer

Indexed keywords

ANIMAL; GENE THERAPY; HUMAN; MALE; METASTASIS; METHODOLOGY; MOUSE; PATHOLOGY; PROSTATE TUMOR; REVIEW;

ANIMAL; GENE THERAPY; HUMAN; MALE; MICE; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035346833     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.3.481     Document Type: Article

References (106)

1. GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA: Cancer statistics, 2000. ÇA Cancer]. Clin. (2000) 50:7-33.
2. LU-YAO GL, MCLERRAN D, WASSONJ, WENNBERG JE: An assessment of radical prostatcctomy. Time trends, geographic variation and outcomes. The prostate patient outcomes research team. JAMA (1993) 269:2633-2636.
3. ADLER HL, MCCURDY MA, RATTAN MV7, TIMME TL, SCARDINO PT, THOMPSON TC: Elevated levels of circulating interleukin-6 and transforming growth factor-betal in patients with metastatic prostatic carcinoma. J Urol. (1999) 161:182-187.
4. MILLER N, WHELAN J: Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum. Gene Ther. (1997) 8:803-815.
5. CURIEL, DT: Strategies to adapt adenoviral vectors for targeted delivery. Ann. NYAcad. Sei. (1999) 886:158-171.
6. RIEGMAN PH, VTJETSTRA RJ, VAN DER KORPUT JA, BRINKMANN AO, TRAPMAN J: The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. (1991) 5:1921-1930.
7. PANG S, TANEJA S, DARDASHTI K et al: Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum. Gene Tber. (1995) 6:1417-1426.
8. SCHUUR ER, HENDERSON GA, KMETEC LA, MILLER JD, LAMPARSKI HG, HENDERSON DR: Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol. Cbem. (1996) 271:7043-7051.
9. CLEUTJENSKB.VANEEKELENCC.VANDERKORPUTHA, BRINKMANN AO, TRAPMAN J: Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol. Chem. (1996) 271:6379-6388.
10. PANG S, DANNULL J, KABOO R et al: Identification of a positive regulatory element responsible for tissuespecific expression of prostate-specific antigen. Cancer Res. (1997) 57:495-499.
11. LATHAM JPF, SEARLE PF, MAUTNER V, JAMES ND: Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. (2000) 60:334-341.
12. HERMAN JR, ADLER HL, AGUILAR-CORDOVA E et al.: In situ gene therapy for adcnocarcinoma of the prostate: a Phase I clinical trial. Hum. Gene Ther. (1999) 10:1239-1249.
13. SHALEV M, KADMON D, TEH BS et al.: Suicide gene therapy toxicity after multiple and repeat injections hi patients with localized prostate cancer. J. Urol. (2000) 163:1747-1750.
14. PRAMUDJI C, SHIMURA S, EBARA S et al.: A novel adenoviral vector regulated by the caveolin-1 promoter for in situ prostate cancer gene therapy. Mot. Ther. (2000) 1:S49 (Abstract 92).
15. MIYATAK, S, MARTUZA RL, RABKIN SD: Defective herpes simplex virus vectors expressing thymldine kinase for the treatment of malignant glioma. Cancer Gene Ther. (1997) 4:222-228.
16. PYLES RB, WARNICK RE, CHALK CL, SZANTI BE, PARYSEK LM: A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. (1997) 8:533-544.
17. WALKER JR, MCGEAGH KG, SUNDARESAN P et al: Local and systemic therapy of human prostate adcnocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Tber. (1999) 10:2237-2243.
18. KAWAKITA M, RAO GS, RITCHEY JK et al.: Effect of canarypox virus (ALVAQ-mediated cytokine expression on murine prostate tumor growth. J. Natl. Cancer Inst. (1997) 89:428-436.
19. BISCHOFF JR, KIRN DH, WILLIAMS A etal.: An adenovirus mutant that replicates selectively hi p53-deficient human tumor cells. Science (1996) 274:373-376.
20. HEISE C, SAMPSON-JOHANNES A, WILLIAMS A, MCCORMICK F, VON HOFF DD, KIRN DH: ONYX-015, an E1B gene-attenuated adcnovirus, causes tumorspecific cytolysis and antitumoral efficacy that can be augmented by standard chcmotherapeutic agents. NatureMed. (1997) 3:639-645-
21. RODRIGUEZ R, SCHUUR ER, LIM HY, HENDERSON GA, SIMONS JW, HENDERSON DR: Prostate attenuated replication competent adcnovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigenpositive prostate cancer cells. Cancer Res. (1997) 57:2559-2563.
22. YU DC, CHEN Y, SENG M, DILLEY J, HENDERSON DR: The addition of adcnovirus Type 5 region E3 enables cahydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. (1999) 59:4200203.
23. YU DC, SAKAMOTO GT, HENDERSON DR: Identification of the transcriptional regulatory sequences of human kallikrcin 2 and their use in the construction of calydon virus 764, an attenuated replication competent adcnovirus for prostate cancer therapy. Cancer Res. (1999) 59:1498-1504.
24. PAIELLI DL, WING MS, ROGULSKIKR et al.: Evaluation of the biodistribution, persistence, toxicity and potential of germ-line transmission of a replication-competent human adcnovirus following intraprostatic administration in the mouse. Mol Tber. (2000) 1:263-274.
25. CHEN Y, YU DC, CHARLTON D, HENDERSON DR: Pre-existent adcnovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum. Gene Tber. (2000) 11:1553-1567.
26. STERMAN DH, TREAT J, LITKZY LA et at.: Adenovirusmediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a Phase I clinical trial in malignant mesothelioma. Hum. Gene Tber. (1998) 9:1083-1092.
27. EASTHAM JA, HALL SJ, SEHGAL I et al.: In vivo gene therapy with p53 or p21 adcnovirus for prostate cancer. Cancer Res. (1995) 55:5151-5155.
28. WANG J, BUCANA C, ROTH J, ZHANG W: Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Tber. (1995) 2:9-17.
29. SWEENEY P, PISTERS LL: Ad5CMVp53 gene therapy for locally advanced prostate cancer - where do we stand? World J. Urol. (2000) 18:121-124.
30. BOULJKAS T: Gene therapy of prostate cancer: p53, suicidal genes and other targets. AntiCancerRes. (1997) 17:1471-1505.
31. THOMPSON TC: In situ gene therapy for prostate cancer. Oncol. 7?es.(1999) 11:1-8.
32. CRAIG C, WERSTO R, KIM M et al.-. A recombinant adenovirus expressing p27Kipl induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene (1997) 14:2283-2289.
33. WANG X, GOROSPE M, HUANG Y, HOLBROOK NJ: p27Kipl overexpression causes apoptotic death of mammalian cells. Oncogene (1997) 15:2991-2997.
34. STEINER MS, ANTHONY CT, LU Y, HOLT JT: Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum. Gene Ther. (1998) 9:747-755.
35. MARCELLI M, CUNNINGHAM GR, WALKUP M et al.: Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res. (1999) 59:382-390.
36. FAN L, FREEMAN KW, KHAN T, PHAM E, SPENCER DM: Improved artificial death switches based on caspascs and FADD. Hum. Gene Ther. (1999) 10:2273-2285.
37. EASTHAM JA, CHEN SH, SEHGALI et al: Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum. Gene Ther. (1996) 7:515-523.
38. GREENE DR, WHEELER TM, EGAWA S, DÜNN JK, SCARDINO PT: A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J. froJ. (1991) 146:1069-1076.
39. EPSTEIN JI, CARMICHAEL MJ, PARTIN AW, WALSH PC: Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications./ Uml. (1994) 151:1587-1592.
40. MÜLLEN CA: Metabolic suicide genes In gene therapy. Pbannacol. Ther. (1994) 63:199-207.
41. MÜLLEN CA, KILSTRUP M, BLAESE RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sei. USA (1992) 89:33-37.
42. PARKER \VB, KING SA, ALLAN P\V et a!.: In vivo gene therapy of cancer with E. coli purine nucleosidc phosphorylase. Hum. Gene Tber. (1997) 8:1637-1644.
43. MOOLTEN FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. (1986) 46:5276-5281.
44. FREYTAG SO, ROGULSKI KR, PAIELLI DL, GILBERT JD, KIM JH: A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene and radiotherapy. Hum. Gene Ther. (1998) 9:1323-3313.
45. MARTINIELLO-WILKS R, GARCIA-ARAGON J, DAJA MM et al.: In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzymedirected prodrug therapy systems delivered by identical adenovirus vectors. Hum. Gene Tber. (1998) 9:1617-1626.
46. FURMAN PA, MCGUIRT PV, KELLER PM, FYFE JA, ELION GB: Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Virology (1980) 102:420-430.
47. MOOLTEN FL: Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther. (1994) 1:279-287.
48. CULVER KW, RAM Z, WALLBRIDGE S, ISHII H, OLDFIELD EH, BLAESE RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 256:1550-1552.
49. FREEMAN SM, ABBOUD CN, WHARTENBY KA et al.: The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. (1993) 53:5274-5283.
50. BI WL, PARYSEK LM, WARNICK R, STAMBROOK PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum. Gene Tber. (1993) 4:725-731-
51. CARUSO M, PANIS Y, GAGANDEEP S, HOUSSIN D, SALZMANN JL, KLATZMANN D: Regression of established macroscopic liver métastases after in situ transduction of a suicide gene. Proc. Katl. Acad. Sei. USA (1993) 90:7024-7028.
52. BARBA D, HARDIN J, SADELAIN M, GAGE F: Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sei. USA (1994) 91:4348-4352.
53. PITTS JD: Cancer gene therapy: a bystander effect using the gap junctional pathway. Mol. Carcinog. (1994) 11:127-130.
54. RAM Z, WALBRIDGE S.SHAWKERT, CULVER KW, BLAESE RM, OLDFIELD EH: The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculaturc and growth of 9L gliomas hi rats. J. Nettrosurg. (1994) 81:256-260.
55. VILE RG, CASTLEDEN S, MARSHALL; etal.: Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and aThl-like profile of intratumoural cytokine expression. Int. J. Cancer (1997) 71:267-274.
56. GAGANDEEP S, BREW R, GREEN B et al.: Prodrugactivated gene therapy: involvement of an immunological component in the 'bystander effect'. Cancer Gene Ther. (1996) 3:83-88.
57. ISHII-MORITA H, AGBARIA R, MÜLLEN ÇA et al.-. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinasc gene therapy model of cancer treatment Gene Tber. (1997) 4:244-251.
58. VILE R, CASTLEDEN S, MARSHALL J, CAMPLEJOHN R, UPTON C, CHONG H: Systemic gene therapy of murine melanoma using tissue specific expression of the HSV tk gene involves an immune component. Cancer Res. (1994) 54:6228-6234.
59. CHEN SH, KOSAI K, XU B etal.: Combination suicide and cytokine gene therapy for hepatic métastases of colon carcinoma: sustained antitumor immunity-prolongs animal survival. Cancer Res. (1996) 56:3758-3762.
60. RAMESH R, MARROGI AJ, MUNSHI A, ABBOUD CN, FREEMAN SM: In vivo analysis of the 'bystander effect': a cytokine cascade. Exp. Hetnatol. (1996) 24:829-838.
61. FREEMAN SM, RAMESH R, SHASTRI M et al: The role of cytokines in mediating the bystander effect using HSV-TKxenogeneic cells. Cancer Lett. (1995) 92:167-174.
62. FELZMANN T, RAMSEY WJ, BLAESE RM: Characterization of the antitumor immune response generated by treatment of murine tumors with rccombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Ther. (1997) 4:1322-1329.
63. CASTLEDEN SA, CHONG H, GARCIA-RIBAS I et al: A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum. Gene Ther. (1997) 8:2087-2102.
64. MELCHER A, TODRYK S, HARDWICK N et al: Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Med. (1998) 4:581-587.
65. MÜLLEN CA, ANDERSON L, WOODS K, NISHINO M, PETROPOULOS D: Ganciclovir chemoablation of herpes thymidine kinasc suicide gene- modified tumors produces tumor necrosis and induces systemic immune responses. Hum. Gene Ther. (1998) 9:2019-2030.
66. HALL SJ, MUTCHNIK SE, CHEN SH, WOO SL, THOMPSON TC: Adenovirus-mediated herpes simplex virus thymidine kinasc gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int.]. Cancer(1997) 70:183-187.
67. COLOMBO BM, BENEDETTI S, OTTOLENGHI S et al.-. The 'bystander effect': association of U-87 cell death with ganciclovir-mcdiatcd apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Tber. (1995) 6:763-772.
68. HAMEL W, MAGNELLI L, CHIARUGI VP, ISRAEL MA: Herpes simplex virus thymidine kinase/ganciclovirmcdiatcd apoptotic death of bystander cells. Cancer Res. (1996) 56:2697-2702.
69. HITT M, BETT AJ, PREVAC L, GRAHAM FL: Construction and propagation of human adenoviral vectors. In: Cell Biology: A Laboratory Handbook. Cells JE, (Ed.), Academic Press, CA USA (1994):479-490.
70. BRAMSON JL, GRAHAM FL, GAULDIE J: The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr. Opin. Biotecbnol. (1995) 6:590-595-
71. THOMPSON TC, SOUTHGATE J, KITCHENER G, LAND H: Multistage carcinogcncsis induced by ras and myc oncogcncs in a reconstituted organ. Cell (1989) 56:917-930.
72. THOMPSON TC, TIMME TL, KADMON D et al.: Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol. Carcinog. (1993) 7:165-179.
73. BALEY PA, YOSHIDA K, QIAN W, SEHGAL I, THOMPSON TC: Progression to androgen inscnsitivity in a novel in vitro mouse model for prostate cancer. J. Steroid Biocbem. Mol. Blol. (1995) 52:403-413-
74. THOMPSON TC, PARK SH, TIMME TL et al.: Loss of p53 function leads to metastasis in ras+myc-initiatcd mouse prostate cancer. Oncogene (1995) 10:869-879.
75. THOMPSON TC, TIMME TL, PARK SH, YANG G, REN C: Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease. Prostate (2000) 43 -.248-254.
76. THOMPSON TC, TIMME TL, SEHGAL I: Oncogenes, growth factors and hormones in prostate cancer. In: Hormones and Growth Factors in Development and Neoplasia. Dickson RB and Salomon DS (Eds.) Wiley-Liss, Inc., NY USA (1998):327-359.
77. HALL SJ, MUTCHNIK SE, YANG G et al.: Cooperative therapeutic effects of androgen ablation and adcno virus- mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Tber. (1999) 6:54-63.
78. TIMME TL, HALL SJ, BARRIOS R e/flJ.:Localinflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice. Cancer Gene Tber. (1998) 5:74-82.
79. MILES BJ, SHALEV M, KADMON D, TIMME TL, THOMPSON TC: Prostate-specific antigen response and systemic T-ccll activation following in situ gene therapy in prostate cancer patients failing radiotherapy. Mol. Tber. (2000) 1:S154 (Abstract 399).
80. AYALA G, WHEELER TM, SHALEV M et al.: Cytopathic effect of n situ gene therapy in prostate cancer. Hum. Patbol. (2000) 31:866-870.
81. BRAMSONJL, HITTM, ADDISON CL étal.: Direct intratumoral injection of an adenovirus expressing interlcukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther. (1996) 7:1995-2002.
82. GATELY MK, RENZETTI LM, MAGRAM J et a!.: The interleukln-12/intcrlcukin-12-reccptor system: role in normal and pathologic immune responses. Ann. Rev. Immunol. (1998) 16:495-521.
83. SCOTT P: IL-12: initiation cytokine for cell-mediated immunity. Science (1993) 260:496-497.
84. GATELY MK: Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors. Cancer Invest. (1993) 11:500-506.
85. WU CY, DEMEURE C, KINIWA M, GATELY M, DELESPESSE G: IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells. / Immunol. (1993) 151:1938-1949.
86. STERN AS, PODLASKIFJ, HULMES JD et al.: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-rymphoblastoid cells. Proc. Natl. Acad. Sei. USA (1990) 87:6808-6812.
87. BRUNDA MJ, LUISTRO L, WARRIER RR et al: Antitumor and antimctastatic activity of intcrlcukin 12 against murine tumors.J. Exp. A fed. (1993) 178:1223-1230.
88. ZOU JP, YAMAMOTO N, FUJII T et al.: Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int. Immunol. (1995) 7:1135-1145.
89. BOGGIO K, NICOLETTI G, DI CARLO E et al.: Interleukin 12-mediated prevention of spontaneous mammary adcnocarcinomas in two lines of Her-2/neu transgenic mice./ Exp. Med. (1998) 188:589-596.
90. SHIMURA S, YANG G, EBARA S, WHEELER TM, FROLOV A, THOMPSON, TC: Reduced infiltration of tumorassociated macrophages in human prostate cancer: association with cancer progression. Cancer Res. (2000) 60:5857-5861.
91. NASU Y, BANGMA CH, HULL GW et al.: Adenovirusmediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung métastases in an orthotopic modeL Gene Tber. (1999) 6:338-349.
92. HULL GW, MCCURDY MA, NASU Y et al.-. Prostate cancer gene therapy: comparison of adcnovims-mediated expression of interlcukin 12 with interlcukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin. CancerRes. (2000) 6:4101-4109.
93. SIDERS WM, WRIGHT P\V, HIXON JA et ah T cell- and NK cell-independent inhibition of hepatic métastases by systemic administration of an IL-12-cxprcssing rccombinant adcnovlrus. J. Immtinol. (1998) 160:5465-5474.
94. HIRSCHOWITZ EA, CRYSTAL RG: Adenovirus-mcdiatcd expression of intcrlcukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung métastases. Am.]. Respir. Cell Mol. Biol. (1999) 20:935-941.
95. MAZZOLINI, G, QIAN, C, XIE X etal: Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adcnovirus expressing interleukin-12. Cancer Gene Ther. (1999) 6:514-522.
96. RAKHM1LEVICH AL, JANSSEN K, HAO Z, SONDEL PM, YANG NS: Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung métastases fia a T-ccllindcpendent mechanism. Cancer Gene Tber. (2000) 7:826-838.
97. WORTH, LL JIA SF, ZHOU Z, CHEN L, KLEINERMAN ES: Intranasal therapy with an adenoviral vector containing the murinc intcrlcukin-12 gene eradicates osteosarcoma lung métastases. Clin. CancerRes. (2000) 6:3713-3718.
98. GATELY MK, WARRIER RR, HONOSAGE S et al.: Administration of rccombinant IL-12 to normal mice enhances cytolytlc lymphocyte activity and induces production of ITN-gamma in vivo. Int. Immunol. (1994) 6:157-167.
99. BANKS, RE, PATEL, PM, SELBY PJ: Interleukin 12: a new clinical player to cytokinc therapy [editorial]. Br. J. Cancer (1995) 71:655-659-
100. SIMONS JW, MIKHAK B, CHANG JF et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophagc colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59:5160-68.
101. ARTHUR JF, BUTTERFIELD LH, ROTH MD et al.: A comparison of gene transfer methods in human dendritic cells. Cancer Gene Tber. (1997) 4:17-25.
102. ZHONG L, GRANELLI-PIPERNO A, CHOI Y, STEINMAN RM: Rccombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur.J. Immunol. (1999) 29:964-972.
103. NISHIOKA Y, H1RAO M, ROBBINS PD, LOTZE MT, TAHARA H: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. CancerRes. (1999) 59:4035041.
104. PUTZER BM, HITT M, MULLER \VJ et a!.: Intcrlcukin 12 and B7-1 costünulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sei. USA (1997) 94:10889-10894.
105. JOKIT, KIKUCHIT, AKASAKIY, SAITOH S, ABE T, OHNO T: Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfcctlon and recombinant interleukin 12. Int. J. Cancer (1999) 82:714-720.
106. CHIKARA M, HUANG H, VLACHAKI M et al: Radio-gene therapy: enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for primary and metastatic prostate cancer. Mol. Tber. (2000) 1:S40 (Abstract 63).